An NAD+ protocol is not one thing. The phrase covers three separate interventions that share an abbreviation, and only one of them has a substantial human trial record behind it. That one is also the one nobody is injecting.
The vendor we point lifters to
NAD+ from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 20, 2026.
Sorting them apart is most of the work on this page, so the sorting comes first.
| Version | What is administered | Route | Controlled human trial record | Organism |
|---|---|---|---|---|
| Oral precursor supplementation | Nicotinamide riboside or nicotinamide mononucleotide | By mouth | Substantial, with blood NAD+ metabolites as the reliable finding | Human |
| Clinic infusion | NAD+ itself | Intravenous, slow, over hours | Very limited; mostly clinic practice and small reports | Human |
| Research vial | NAD+ itself | Subcutaneous injection | Effectively none in controlled form | Human |
| Preclinical NAD manipulation | Precursors or enzyme targets | Various | Not applicable, this is animal work | Mouse |
| Any of the above, for muscle mass or strength | Any | Any | No such outcome reported | None |
The last row is the one that matters on a site about lean mass, and it is empty for every version.
Three things share the name NAD+ protocol
The first version is a supplement regimen. Someone takes capsules of a precursor, which is absorbed and converted inside the body through the salvage pathway toward NAD+. This is the version almost every published human trial studied.
The second is an infusion appointment. A clinic administers NAD+ directly into a vein, slowly, usually across several hours, sometimes repeated over consecutive days. The slowness is not therapeutic sophistication. It is tolerability management, because faster infusion is reported to be unpleasant.
The third is a vial bought as research material and injected subcutaneously. This has the least behind it of the three, no approved product anywhere, and no controlled trial defining what it does.
When a search result says "protocol", it is usually describing the second or third while borrowing credibility from the first.
The oral precursor studies, where the real record is
Here the evidence is genuinely substantial, and it deserves to be described accurately rather than dismissed.
Trials of oral nicotinamide riboside and of oral nicotinamide mononucleotide in humans have repeatedly reported that these compounds raise NAD+ related metabolites measured in blood. That finding is robust. The compounds were also generally tolerated in the populations studied over the durations studied.
Beyond that, the record becomes inconsistent. Functional outcomes have varied between trials, and in older adults, where the interest is highest, trials that examined skeletal muscle rather than blood reported that the muscle level effects were limited or absent even when the blood measurement rose.
That dissociation is the most useful result in this entire field for a lifter. It shows that the marker and the tissue can move independently, which means a rising blood number is not evidence that anything happened where it counts.
The infusion clinic version, and what it is built around
An infusion protocol is structured around the infusion reaction, not around an outcome.
People receiving intravenous NAD+ commonly report nausea, chest tightness, flushing and cramping when the rate is increased, and the practical response is to slow the drip. That is the organising principle of the appointment length.
What the appointment is meant to achieve is asserted rather than demonstrated. Controlled trials of intravenous NAD+ with meaningful outcome measures are scarce, and the setting itself makes the reported benefits hard to interpret: an expensive appointment, hours in a chair, attentive staff and an explicit promise of energy is close to a maximal placebo condition. Anything measured as a subjective feeling in that context needs a control group to mean anything, and it usually does not have one.
The vial bought as research material
This version has the least support and the most confident marketing.
Beyond the absence of controlled trials, there is an unresolved mechanistic problem. NAD+ is a large, charged dinucleotide, and published biochemistry describes extracellular NAD+ being broken down by cell surface enzymes into smaller pieces, including nicotinamide riboside and nicotinamide, before uptake occurs. If that is what happens after an injection, the intervention amounts to delivering precursors by a more invasive route.
That argument is mechanistic and not settled, and it should not be stated as a conclusion. It is enough, though, to block the move people most want to make: borrowing the oral precursor literature as evidence for the injected product. The two cannot be assumed to be the same intervention when the biochemistry suggests one may partly convert into the other on the way in.
Added to that are the ordinary problems of an unapproved product. No pharmacopoeial standard, no batch release anyone is accountable for, no verified concentration, and sterility asserted by a seller.
The measurement none of these versions include
Not one of the three versions, as practised, measures the thing this audience cares about.
Blood NAD+ metabolites are measured in trials, and they are the wrong tissue. Subjective energy is reported in clinics, and it is the wrong kind of evidence without a control group. Neither body composition nor strength appears as an endpoint in any of it.
So a reader trying to work out whether an NAD protocol protects ageing muscle is asking a question that has never been put to a study. The absence is not a gap in the reporting. It is a gap in what was done.
Why the mechanism does not predict a muscle result anyway
NAD+ has two jobs. It cycles between oxidised and reduced forms as the electron carrier in energy metabolism, and it is consumed as a substrate by enzymes including sirtuins, PARPs and CD38.
Neither job is a growth signal. There is no described interaction with myostatin, with satellite cell behaviour or with muscle protein synthesis, in any species. The plausible connection to this audience runs through mitochondrial function and fatigue resistance, which is a training capacity argument rather than a hypertrophy argument, and even that has not been demonstrated to improve in human muscle following supplementation.
Stating it plainly: there is no muscle mass or strength outcome to claim for oral precursors or for injected NAD+, and no mechanism that would lead anyone to expect one.
The rodent results, and the distance to a person
Much of the enthusiasm in this field traces back to mouse work, and it is worth stating what that work was and was not.
In mice, raising NAD availability through precursors has been reported to improve mitochondrial and metabolic measures, and in aged animals to affect markers of tissue function. These are real experiments and they are the reason the human trials were funded.
Two things limit how far they travel. Mouse NAD metabolism, lifespan and muscle biology differ from human versions in ways that have repeatedly turned promising rodent findings into null human ones, and this field has already produced that pattern once: the blood measurement rose in people, the muscle level effect largely did not. And the rodent protocols administered precursors, so even within the animal literature the intervention is usually not injected NAD+.
Anyone citing mouse data as support for a human injection protocol is therefore making two leaps at once, across species and across intervention, and the second leap is the one nobody mentions.
What a protocol worth copying would contain
It would specify which molecule, by which route, since those are currently blurred. It would include a placebo group, because the reported benefit is largely subjective. It would sample skeletal muscle rather than blood, because the blood result is already known and has failed to predict the tissue result. It would measure body composition and strength. And it would run long enough for a change in muscle to be possible.
Nothing like that has been published for the injected form. Until it is, what circulates under the word protocol is a description of habits, not a summary of findings.
Questions people ask about these regimens
Does the large NAD research literature support injecting it?
Most of that literature studies oral precursors. Transferring it to an injected product without naming which intervention was tested is the central error in this subject.
Is a clinic infusion schedule evidence of anything?
It is evidence of what clinics do. The pacing exists to manage the discomfort of the infusion, and the outcomes are mostly uncontrolled subjective reports collected from people who have already paid for the appointment.
Has any protocol measured muscle?
No published protocol of either form has reported muscle mass or strength as an outcome. Where skeletal muscle was examined at all, it was for mitochondrial and metabolic measures.
Is any version of this approved?
Oral precursors are sold as supplements rather than approved medicines. Injected NAD+ has no marketing authorisation as a medicine in any market.